Krystal Biotech Inc (KRYS)
Debt-to-equity ratio
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 799,242 | 778,641 | 755,948 | 653,114 | 489,566 | 522,231 | 540,772 | 559,181 | 548,554 | 593,576 | 408,237 | 418,540 | 430,652 | 292,084 | 301,720 | 309,696 | 198,369 | 202,914 | 207,646 | 198,290 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
March 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $799,242K
= 0.00
The debt-to-equity ratio of Krystal Biotech Inc has consistently been reported as 0.00 for all the periods listed in the table. This indicates that the company has not reported any debt on its balance sheet during these periods, leading to a debt-to-equity ratio of zero. A debt-to-equity ratio of zero suggests that the company is entirely funded by equity, indicating a low financial risk as there is no debt that needs to be repaid. It also implies that the company may not have taken on any external borrowing to finance its operations or investments during these periods. It is important to note that a debt-to-equity ratio of zero may not always be ideal depending on the company's growth and capital needs, but in this case, it appears to reflect a conservative financial strategy.
Peer comparison
Mar 31, 2024